<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 4.1d -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: ifit10q093014.xfr; Date: 2014%2D11%2D06T17:14:40 -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80010000 -->
<xbrli:xbrl xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2014-01-31" xmlns:us-roles="http://fasb.org/us-roles/2014-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ifit="http://isatori.com/20140930">
    <link:schemaRef xlink:href="ifit-20140930.xsd" xlink:type="simple" />
    <xbrli:context id="From2014-01-01to2014-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000741114</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000741114</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000741114</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-07-01to2014-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000741114</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-07-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-07-01to2013-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000741114</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-07-01</xbrli:startDate>
        <xbrli:endDate>2013-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000741114</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000741114</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000741114</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-07-01to2014-09-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000741114</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-07-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-07-01to2013-09-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000741114</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-07-01</xbrli:startDate>
        <xbrli:endDate>2013-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-09-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000741114</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-09-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000741114</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-07-01to2014-09-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000741114</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-07-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-07-01to2013-09-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000741114</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-07-01</xbrli:startDate>
        <xbrli:endDate>2013-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-09-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000741114</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-09-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000741114</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-09-30_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueProductLineMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000741114</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-09-30_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueProductLineMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000741114</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-09-30_us-gaap_CustomerConcentrationRiskMember_us-gaap_AccountsReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000741114</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-09-30_us-gaap_CustomerConcentrationRiskMember_us-gaap_AccountsReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000741114</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000741114</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-07-16">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000741114</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-07-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000741114</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000741114</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000741114</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000741114</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000741114</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000741114</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-09-30_us-gaap_SupplierConcentrationRiskMember_us-gaap_CostOfGoodsProductLineMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000741114</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsProductLineMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-09-30_us-gaap_SupplierConcentrationRiskMember_us-gaap_CostOfGoodsProductLineMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000741114</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsProductLineMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-09-30_us-gaap_SupplierConcentrationRiskMember_us-gaap_LiabilitiesTotalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000741114</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:LiabilitiesTotalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-09-30_us-gaap_SupplierConcentrationRiskMember_us-gaap_LiabilitiesTotalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000741114</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:LiabilitiesTotalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-09-30_us-gaap_FairValueInputsLevel1Member_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000741114</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-09-30_us-gaap_FairValueInputsLevel1Member_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000741114</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-09-30_us-gaap_FairValueInputsLevel3Member_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000741114</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-09-30_us-gaap_FairValueInputsLevel3Member_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000741114</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-09-30_us-gaap_FairValueInputsLevel2Member_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000741114</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-09-30_us-gaap_FairValueInputsLevel2Member_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000741114</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000741114</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000741114</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000741114</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-11-04">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000741114</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-11-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-09-30_custom_WarrantGrantsBreakwaterMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000741114</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ifit:WarrantGrantsBreakwaterMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-09-30_custom_WarrantGrantsBreakwaterMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000741114</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ifit:WarrantGrantsBreakwaterMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-07-01to2014-09-30_custom_WarrantGrantsBreakwaterMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000741114</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ifit:WarrantGrantsBreakwaterMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-07-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-07-01to2013-09-30_custom_WarrantGrantsBreakwaterMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000741114</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ifit:WarrantGrantsBreakwaterMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-07-01</xbrli:startDate>
        <xbrli:endDate>2013-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-09-30_custom_WarrantGrantsBreakwaterMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000741114</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ifit:WarrantGrantsBreakwaterMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-09-30_custom_BusinessDevelopmentConsultantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000741114</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ifit:BusinessDevelopmentConsultantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-09-30_custom_BusinessDevelopmentConsultantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000741114</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ifit:BusinessDevelopmentConsultantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-09-30_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000741114</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-09-30_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000741114</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-09-30_custom_OptionGrantTwoCompanyEmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000741114</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ifit:OptionGrantTwoCompanyEmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-09-30_custom_OptionGrantTwoCompanyEmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000741114</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ifit:OptionGrantTwoCompanyEmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-09-30_us-gaap_StockOptionMember1065286383">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000741114</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-07-01to2014-09-30_us-gaap_StockOptionMember1065286383">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000741114</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-07-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-10-01to2014-10-30_us-gaap_SubsequentEventMember_custom_LeaseArrangementTypeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000741114</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">ifit:LeaseArrangementTypeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-10-01</xbrli:startDate>
        <xbrli:endDate>2014-10-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Percent">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <dei:EntityRegistrantName contextRef="From2014-01-01to2014-09-30">iSatori, Inc.</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey contextRef="From2014-01-01to2014-09-30">0000741114</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="From2014-01-01to2014-09-30">10-Q</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2014-01-01to2014-09-30">2014-09-30</dei:DocumentPeriodEndDate>
    <dei:AmendmentFlag contextRef="From2014-01-01to2014-09-30">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2014-01-01to2014-09-30">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2014-01-01to2014-09-30">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2014-01-01to2014-09-30">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2014-01-01to2014-09-30">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityFilerCategory contextRef="From2014-01-01to2014-09-30">Smaller Reporting Company</dei:EntityFilerCategory>
    <dei:DocumentFiscalPeriodFocus contextRef="From2014-01-01to2014-09-30">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="From2014-01-01to2014-09-30">2014</dei:DocumentFiscalYearFocus>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">822876</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">1153865</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">1655453</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2013-09-30" unitRef="USD" decimals="0">1040139</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">2398178</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">1893580</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:FIFOInventoryAmount contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">1985764</us-gaap:FIFOInventoryAmount>
    <us-gaap:FIFOInventoryAmount contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">2646307</us-gaap:FIFOInventoryAmount>
    <us-gaap:IncomeTaxReceivable contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">102452</us-gaap:IncomeTaxReceivable>
    <us-gaap:IncomeTaxReceivable contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">0</us-gaap:IncomeTaxReceivable>
    <us-gaap:NotesAndLoansReceivableGrossCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">11013</us-gaap:NotesAndLoansReceivableGrossCurrent>
    <us-gaap:NotesAndLoansReceivableGrossCurrent contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">3814</us-gaap:NotesAndLoansReceivableGrossCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">108228</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">42311</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:DeferredTaxAssetsNetCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">53081</us-gaap:DeferredTaxAssetsNetCurrent>
    <us-gaap:DeferredTaxAssetsNetCurrent contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">9156</us-gaap:DeferredTaxAssetsNetCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">222466</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">245265</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">5704058</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">5994298</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">173636</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">147781</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:NotesReceivableNet contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">81714</us-gaap:NotesReceivableNet>
    <us-gaap:NotesReceivableNet contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">81714</us-gaap:NotesReceivableNet>
    <us-gaap:DeferredTaxAssetsNet contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">147941</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">170912</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DepositsAssetsNoncurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">61167</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:DepositsAssetsNoncurrent contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">43120</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:OtherAssets contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">209108</us-gaap:OtherAssets>
    <us-gaap:OtherAssets contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">214032</us-gaap:OtherAssets>
    <us-gaap:Assets contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">6168516</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">6437825</us-gaap:Assets>
    <us-gaap:AccountsPayableTradeCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">1248490</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">1288277</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">187608</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">237608</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DeferredRevenueCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">292215</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">210002</us-gaap:DeferredRevenueCurrent>
    <us-gaap:LinesOfCreditCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">1220655</us-gaap:LinesOfCreditCurrent>
    <us-gaap:LinesOfCreditCurrent contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">1620519</us-gaap:LinesOfCreditCurrent>
    <us-gaap:NotesPayableCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">20464</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">16925</us-gaap:NotesPayableCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">2969432</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">3373331</us-gaap:LiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">471015</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">226445</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:CommitmentsAndContingencies contextRef="AsOf2013-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:CommitmentsAndContingencies contextRef="AsOf2014-09-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:PreferredStockValue contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">225</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">225</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">128797</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">128969</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">4731535</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">4778079</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">-2132488</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">-2069224</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">2728069</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">2838049</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">6168516</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">6437825</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2013-12-31" unitRef="USDPShares" decimals="INF">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2014-09-30" unitRef="USDPShares" decimals="INF">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2013-12-31" unitRef="Shares" decimals="INF">750000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2014-09-30" unitRef="Shares" decimals="INF">750000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2013-12-31" unitRef="Shares" decimals="INF">22500</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2014-09-30" unitRef="Shares" decimals="INF">22500</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2013-12-31" unitRef="Shares" decimals="INF">22500</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2014-09-30" unitRef="Shares" decimals="INF">22500</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockLiquidationPreference contextRef="AsOf2013-12-31" unitRef="USDPShares" decimals="INF">450000</us-gaap:PreferredStockLiquidationPreference>
    <us-gaap:PreferredStockLiquidationPreference contextRef="AsOf2014-09-30" unitRef="USDPShares" decimals="INF">450000</us-gaap:PreferredStockLiquidationPreference>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2013-12-31" unitRef="USDPShares" decimals="INF">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2014-09-30" unitRef="USDPShares" decimals="INF">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2014-09-30_custom_BusinessDevelopmentConsultantMember" unitRef="USDPShares" decimals="INF">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2013-12-31" unitRef="Shares" decimals="INF">56250000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2014-09-30" unitRef="Shares" decimals="INF">56250000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2013-12-31" unitRef="Shares" decimals="INF">12879651</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2014-09-30" unitRef="Shares" decimals="INF">12896852</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2013-12-31" unitRef="Shares" decimals="INF">12879651</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2014-09-30" unitRef="Shares" decimals="INF">12896852</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:AccountsAndNotesReceivableNet contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">2398178</us-gaap:AccountsAndNotesReceivableNet>
    <us-gaap:AccountsAndNotesReceivableNet contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">1893580</us-gaap:AccountsAndNotesReceivableNet>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">1248490</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">1276642</us-gaap:AccountsPayableCurrent>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">822876</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">1153865</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AccountsReceivableFairValueDisclosure contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">2398178</us-gaap:AccountsReceivableFairValueDisclosure>
    <us-gaap:AccountsReceivableFairValueDisclosure contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">1893580</us-gaap:AccountsReceivableFairValueDisclosure>
    <us-gaap:AccountsPayableFairValueDisclosure contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">1248490</us-gaap:AccountsPayableFairValueDisclosure>
    <us-gaap:AccountsPayableFairValueDisclosure contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">1276642</us-gaap:AccountsPayableFairValueDisclosure>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">471015</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">226445</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:AccountsReceivableGrossCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">2323522</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AccountsReceivableGrossCurrent contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">1834174</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:OtherReceivablesGrossCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">74656</us-gaap:OtherReceivablesGrossCurrent>
    <us-gaap:OtherReceivablesGrossCurrent contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">59406</us-gaap:OtherReceivablesGrossCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">0</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">0</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:OtherInventoryPurchasedGoods contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">120057</us-gaap:OtherInventoryPurchasedGoods>
    <us-gaap:OtherInventoryPurchasedGoods contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">170189</us-gaap:OtherInventoryPurchasedGoods>
    <us-gaap:InventoryRawMaterialsAndSupplies contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">207320</us-gaap:InventoryRawMaterialsAndSupplies>
    <us-gaap:InventoryRawMaterialsAndSupplies contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">284560</us-gaap:InventoryRawMaterialsAndSupplies>
    <us-gaap:InventoryFinishedGoods contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">1658387</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">2191558</us-gaap:InventoryFinishedGoods>
    <us-gaap:SalesReturnsAndAllowancesGoods contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">85000</us-gaap:SalesReturnsAndAllowancesGoods>
    <us-gaap:SalesReturnsAndAllowancesGoods contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">70000</us-gaap:SalesReturnsAndAllowancesGoods>
    <us-gaap:NotesReceivableGross contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">85528</us-gaap:NotesReceivableGross>
    <us-gaap:AccountsReceivableAdditionalNarrativeDisclosure contextRef="From2014-01-01to2014-09-30">The predecessor company disposed of a dormant product line of vitamins in December 2010. As part of the consideration in this divestiture, the Company received from the purchaser of this product line an unsecured note in the amount of $170,000. The original note was due to be repaid on or before March 2014, where interest accrued principally at an annual rate of 5%, based upon the initial $170,000 principal and was payable monthly. As of March 31, 2013, the note was novated and a new promissory note was issued to reflect a modification in the payment terms, which includes no interest.</us-gaap:AccountsReceivableAdditionalNarrativeDisclosure>
    <us-gaap:ReceivableWithImputedInterestDueDates contextRef="From2014-01-01to2014-09-30">2017-05-01</us-gaap:ReceivableWithImputedInterestDueDates>
    <us-gaap:SalesDiscountsReturnsAndAllowancesGoods contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">2200761</us-gaap:SalesDiscountsReturnsAndAllowancesGoods>
    <us-gaap:SalesDiscountsReturnsAndAllowancesGoods contextRef="From2014-07-01to2014-09-30" unitRef="USD" decimals="0">840670</us-gaap:SalesDiscountsReturnsAndAllowancesGoods>
    <us-gaap:SalesDiscountsReturnsAndAllowancesGoods contextRef="From2013-07-01to2013-09-30" unitRef="USD" decimals="0">484296</us-gaap:SalesDiscountsReturnsAndAllowancesGoods>
    <us-gaap:SalesDiscountsReturnsAndAllowancesGoods contextRef="From2013-01-01to2013-09-30" unitRef="USD" decimals="0">1492824</us-gaap:SalesDiscountsReturnsAndAllowancesGoods>
    <us-gaap:OperatingLeasesRentExpenseNet contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">62147</us-gaap:OperatingLeasesRentExpenseNet>
    <us-gaap:OperatingLeasesRentExpenseNet contextRef="From2014-07-01to2014-09-30" unitRef="USD" decimals="0">20716</us-gaap:OperatingLeasesRentExpenseNet>
    <us-gaap:OperatingLeasesRentExpenseNet contextRef="From2013-07-01to2013-09-30" unitRef="USD" decimals="0">20716</us-gaap:OperatingLeasesRentExpenseNet>
    <us-gaap:OperatingLeasesRentExpenseNet contextRef="From2013-01-01to2013-09-30" unitRef="USD" decimals="0">62147</us-gaap:OperatingLeasesRentExpenseNet>
    <us-gaap:DescriptionOfLesseeLeasingArrangementsOperatingLeases contextRef="From2014-01-01to2014-09-30">The Company leases its headquarters facility, comprising approximately 10,044 square feet, in Golden, Colorado. The lease term expires January 31, 2017 and requires equal monthly payments over the remaining term.</us-gaap:DescriptionOfLesseeLeasingArrangementsOperatingLeases>
    <us-gaap:DescriptionOfLesseeLeasingArrangementsOperatingLeases contextRef="From2014-10-01to2014-10-30_us-gaap_SubsequentEventMember_custom_LeaseArrangementTypeMember">The Company executed a 50-month lease of a 17,426 square foot building in Denver, CO to accommodate the growth in inventory and support warehouse operations. The warehouse operations will be moved prior to year end from its current location at the Golden, CO headquarters.</us-gaap:DescriptionOfLesseeLeasingArrangementsOperatingLeases>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">193347</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <us-gaap:DeferredAdvertisingCosts contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">7651</us-gaap:DeferredAdvertisingCosts>
    <us-gaap:DeferredAdvertisingCosts contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">0</us-gaap:DeferredAdvertisingCosts>
    <us-gaap:MarketingExpense contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">1252698</us-gaap:MarketingExpense>
    <us-gaap:MarketingExpense contextRef="From2014-07-01to2014-09-30" unitRef="USD" decimals="0">310580</us-gaap:MarketingExpense>
    <us-gaap:MarketingExpense contextRef="From2013-07-01to2013-09-30" unitRef="USD" decimals="0">1005858</us-gaap:MarketingExpense>
    <us-gaap:MarketingExpense contextRef="From2013-01-01to2013-09-30" unitRef="USD" decimals="0">1330788</us-gaap:MarketingExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">67907</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2014-07-01to2014-09-30" unitRef="USD" decimals="0">57002</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2013-07-01to2013-09-30" unitRef="USD" decimals="0">68071</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2013-01-01to2013-09-30" unitRef="USD" decimals="0">155836</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">97349</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="From2014-07-01to2014-09-30" unitRef="USD" decimals="0">18144</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="From2013-07-01to2013-09-30" unitRef="USD" decimals="0">73608</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="From2013-01-01to2013-09-30" unitRef="USD" decimals="0">-110606</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="From2014-01-01to2014-09-30_custom_BusinessDevelopmentConsultantMember" unitRef="Shares" decimals="INF">7500</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2014-01-01to2014-09-30_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2014-01-01to2014-09-30_custom_OptionGrantTwoCompanyEmployeesMember" unitRef="Shares" decimals="INF">6000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2014-09-30_us-gaap_EmployeeStockOptionMember" unitRef="USDPShares" decimals="INF">2.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2014-09-30_custom_OptionGrantTwoCompanyEmployeesMember" unitRef="USDPShares" decimals="INF">2.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="From2014-01-01to2014-09-30_custom_WarrantGrantsBreakwaterMember" unitRef="Shares" decimals="INF">420549</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees contextRef="From2014-01-01to2014-09-30_custom_WarrantGrantsBreakwaterMember">The company issued warrants to purchase 3% of fully diluted shares of the common stock of the Company to Breakwater Structured Growth Opportunity Fund, L.P., with an imputed exercise price equal to approximately one-hundredth of a dollar in connection with a $1.025 million subordinated mezzanine loan arrangements.</us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="From2014-01-01to2014-09-30_custom_WarrantGrantsBreakwaterMember">2016-06-15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="From2014-01-01to2014-09-30_us-gaap_EmployeeStockOptionMember">2023-10-15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="From2014-01-01to2014-09-30_custom_OptionGrantTwoCompanyEmployeesMember">2024-02-10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights contextRef="From2014-01-01to2014-09-30_custom_WarrantGrantsBreakwaterMember">Fully vested</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights contextRef="From2014-01-01to2014-09-30_us-gaap_EmployeeStockOptionMember">Three year vesting schedules of 1/3 each year through October 2016.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights contextRef="From2014-01-01to2014-09-30_custom_OptionGrantTwoCompanyEmployeesMember">Three year vesting schedules of 1/3 each year through February 2017.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed contextRef="From2014-01-01to2014-09-30_custom_WarrantGrantsBreakwaterMember">The Company used a lattice model in developing a fair value for the Breakwater warrant obligation at September 30, 2014, using a quoted stock value of $0.55 per share, which represents a discount of 50% from the closing stock price. This reduction was based on the application of a discount for lack of liquidity.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate contextRef="From2014-01-01to2014-09-30_custom_WarrantGrantsBreakwaterMember" unitRef="Percent" decimals="INF">0.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate contextRef="From2014-01-01to2014-09-30_us-gaap_EmployeeStockOptionMember" unitRef="Percent" decimals="INF">0.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate contextRef="From2014-01-01to2014-09-30_custom_OptionGrantTwoCompanyEmployeesMember" unitRef="Percent" decimals="INF">0.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate>
    <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="From2014-01-01to2014-09-30_custom_WarrantGrantsBreakwaterMember" unitRef="Percent" decimals="INF">0.0058</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="From2014-01-01to2014-09-30_us-gaap_EmployeeStockOptionMember" unitRef="Percent" decimals="INF">0.0213</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="From2014-01-01to2014-09-30_custom_OptionGrantTwoCompanyEmployeesMember" unitRef="Percent" decimals="INF">0.0213</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="From2014-01-01to2014-09-30_us-gaap_EmployeeStockOptionMember" unitRef="Percent" decimals="INF">0.0241</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="From2014-01-01to2014-09-30_custom_OptionGrantTwoCompanyEmployeesMember" unitRef="Percent" decimals="INF">0.0241</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:SharePrice contextRef="AsOf2014-09-30_custom_WarrantGrantsBreakwaterMember" unitRef="USDPShares" decimals="INF">.55</us-gaap:SharePrice>
    <us-gaap:SharePrice contextRef="AsOf2014-09-30_custom_BusinessDevelopmentConsultantMember" unitRef="USDPShares" decimals="INF">2.17</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="From2014-07-01to2014-09-30_us-gaap_StockOptionMember" unitRef="USDPShares" decimals="INF">0.573</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="From2013-07-01to2013-09-30_us-gaap_StockOptionMember" unitRef="USDPShares" decimals="INF">0.573</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="From2014-01-01to2014-09-30_us-gaap_StockOptionMember" unitRef="USDPShares" decimals="INF">0.573</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="From2013-01-01to2013-09-30_us-gaap_StockOptionMember" unitRef="USDPShares" decimals="INF">0.573</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="From2014-07-01to2014-09-30_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">0.001</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="From2013-07-01to2013-09-30_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">0.001</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="From2014-01-01to2014-09-30_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">0.001</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="From2013-01-01to2013-09-30_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">0.001</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="From2014-01-01to2014-09-30_us-gaap_EmployeeStockOptionMember" unitRef="USDPShares" decimals="INF">1.11</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="From2014-01-01to2014-09-30_custom_OptionGrantTwoCompanyEmployeesMember" unitRef="USDPShares" decimals="INF">1.11</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="From2014-07-01to2014-09-30_us-gaap_StockOptionMember" unitRef="USDPShares" decimals="INF">2.50</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="From2013-07-01to2013-09-30_us-gaap_StockOptionMember" unitRef="USDPShares" decimals="INF">2.50</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="From2014-01-01to2014-09-30_us-gaap_StockOptionMember" unitRef="USDPShares" decimals="INF">2.50</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="From2013-01-01to2013-09-30_us-gaap_StockOptionMember" unitRef="USDPShares" decimals="INF">2.50</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="From2014-07-01to2014-09-30_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">2.25</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="From2013-07-01to2013-09-30_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">2.25</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="From2014-01-01to2014-09-30_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">2.25</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="From2013-01-01to2013-09-30_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">2.25</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="From2014-01-01to2014-09-30_us-gaap_EmployeeStockOptionMember" unitRef="USDPShares" decimals="INF">1.25</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="From2014-01-01to2014-09-30_custom_OptionGrantTwoCompanyEmployeesMember" unitRef="USDPShares" decimals="INF">1.25</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <ifit:StockPriceRange contextRef="From2014-01-01to2014-09-30_custom_WarrantGrantsBreakwaterMember">1.05332062 to .94937855</ifit:StockPriceRange>
    <ifit:RiskNeutralProbabilitiesRange contextRef="From2014-01-01to2014-09-30_custom_WarrantGrantsBreakwaterMember">.48808915 to .51191085</ifit:RiskNeutralProbabilitiesRange>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="From2014-01-01to2014-09-30_custom_WarrantGrantsBreakwaterMember">P1Y9M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <ifit:WeightedAverageExpectedTermMinimum contextRef="From2014-01-01to2014-09-30_us-gaap_EmployeeStockOptionMember">P6Y1M</ifit:WeightedAverageExpectedTermMinimum>
    <ifit:WeightedAverageExpectedTermMinimum contextRef="From2014-01-01to2014-09-30_custom_OptionGrantTwoCompanyEmployeesMember">P6Y1M</ifit:WeightedAverageExpectedTermMinimum>
    <ifit:WeightedAverageExpectedTermMaximum contextRef="From2014-01-01to2014-09-30_us-gaap_EmployeeStockOptionMember">P6Y4M</ifit:WeightedAverageExpectedTermMaximum>
    <ifit:WeightedAverageExpectedTermMaximum contextRef="From2014-01-01to2014-09-30_custom_OptionGrantTwoCompanyEmployeesMember">P6Y4M</ifit:WeightedAverageExpectedTermMaximum>
    <us-gaap:FairValueAssumptionsWeightedAverageVolatilityRate contextRef="From2014-01-01to2014-09-30_custom_WarrantGrantsBreakwaterMember" unitRef="Percent" decimals="INF">0.3746</us-gaap:FairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:FairValueAssumptionsWeightedAverageVolatilityRate contextRef="From2014-01-01to2014-09-30_us-gaap_EmployeeStockOptionMember" unitRef="Percent" decimals="INF">0.3522</us-gaap:FairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:FairValueAssumptionsWeightedAverageVolatilityRate contextRef="From2014-01-01to2014-09-30_custom_OptionGrantTwoCompanyEmployeesMember" unitRef="Percent" decimals="INF">0.3522</us-gaap:FairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">10087</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2014-07-01to2014-09-30" unitRef="USD" decimals="0">1961</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2014-01-01to2014-09-30_custom_BusinessDevelopmentConsultantMember" unitRef="USD" decimals="0">16275</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2014-01-01to2014-09-30_us-gaap_StockOptionMember1065286383" unitRef="USD" decimals="0">17474</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2014-07-01to2014-09-30_us-gaap_StockOptionMember1065286383" unitRef="USD" decimals="0">5352</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:OtherOperatingIncome contextRef="From2014-01-01to2014-09-30_custom_WarrantGrantsBreakwaterMember" unitRef="USD" decimals="0">244570</us-gaap:OtherOperatingIncome>
    <us-gaap:OtherOperatingIncome contextRef="From2014-07-01to2014-09-30_custom_WarrantGrantsBreakwaterMember" unitRef="USD" decimals="0">52568</us-gaap:OtherOperatingIncome>
    <us-gaap:OtherOperatingIncome contextRef="From2013-07-01to2013-09-30_custom_WarrantGrantsBreakwaterMember" unitRef="USD" decimals="0">41501</us-gaap:OtherOperatingIncome>
    <us-gaap:OtherOperatingIncome contextRef="From2013-01-01to2013-09-30_custom_WarrantGrantsBreakwaterMember" unitRef="USD" decimals="0">71398</us-gaap:OtherOperatingIncome>
    <us-gaap:LineOfCredit contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">2000000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit contextRef="AsOf2012-07-16" unitRef="USD" decimals="0">1500000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCreditFacilityInterestRateDescription contextRef="From2014-01-01to2014-09-30">The principal balance will note bear interest at the one month USD LIBOR rate measured not more often than once per month (the "Index").  Interest on any unpaid balance will bear interest at the Index plus 3.750% with a minimum interest rate of 4.00% per annum and is payable monthly.</us-gaap:LineOfCreditFacilityInterestRateDescription>
    <us-gaap:DerivativeLiabilities contextRef="AsOf2013-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" unitRef="USD" decimals="0">108228</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="AsOf2012-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" unitRef="USD" decimals="0">29338</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="AsOf2013-12-31_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember_us-gaap_FairValueInputsLevel3Member" unitRef="USD" decimals="0">471015</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="AsOf2012-12-31_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember_us-gaap_FairValueInputsLevel3Member" unitRef="USD" decimals="0">701852</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="AsOf2014-09-30_us-gaap_FairValueInputsLevel1Member_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" unitRef="USD" decimals="0">42311</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="AsOf2014-09-30_us-gaap_FairValueInputsLevel3Member_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" unitRef="USD" decimals="0">226445</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="AsOf2014-09-30_us-gaap_FairValueInputsLevel2Member_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" unitRef="USD" decimals="0">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="AsOf2013-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" unitRef="USD" decimals="0">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="AsOf2012-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" unitRef="USD" decimals="0">0</us-gaap:DerivativeLiabilities>
    <us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">108228</us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure>
    <us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure contextRef="AsOf2014-09-30" unitRef="USD" decimals="0">42311</us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2014-01-01to2014-09-30_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueProductLineMember" unitRef="Percent" decimals="INF">0.60</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2013-01-01to2013-09-30_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueProductLineMember" unitRef="Percent" decimals="INF">0.56</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2014-01-01to2014-09-30_us-gaap_CustomerConcentrationRiskMember_us-gaap_AccountsReceivableMember" unitRef="Percent" decimals="INF">0.56</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2013-01-01to2013-09-30_us-gaap_CustomerConcentrationRiskMember_us-gaap_AccountsReceivableMember" unitRef="Percent" decimals="INF">0.65</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2014-01-01to2014-09-30_us-gaap_SupplierConcentrationRiskMember_us-gaap_CostOfGoodsProductLineMember" unitRef="Percent" decimals="INF">0.70</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2013-01-01to2013-09-30_us-gaap_SupplierConcentrationRiskMember_us-gaap_CostOfGoodsProductLineMember" unitRef="Percent" decimals="INF">0.73</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2014-01-01to2014-09-30_us-gaap_SupplierConcentrationRiskMember_us-gaap_LiabilitiesTotalMember" unitRef="Percent" decimals="INF">0.58</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2013-01-01to2013-09-30_us-gaap_SupplierConcentrationRiskMember_us-gaap_LiabilitiesTotalMember" unitRef="Percent" decimals="INF">0.43</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="From2013-01-01to2013-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" unitRef="USD" decimals="0">114993</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="From2013-01-01to2013-12-31_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember_us-gaap_FairValueInputsLevel3Member" unitRef="USD" decimals="0">-143082</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="From2014-01-01to2014-09-30_us-gaap_FairValueInputsLevel1Member_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" unitRef="USD" decimals="0">49964</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="From2014-01-01to2014-09-30_us-gaap_FairValueInputsLevel3Member_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" unitRef="USD" decimals="0">-244570</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="From2014-01-01to2014-09-30_us-gaap_FairValueInputsLevel2Member_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" unitRef="USD" decimals="0">0</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="From2013-01-01to2013-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" unitRef="USD" decimals="0">0</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:LiabilitiesFairValueAdjustment contextRef="From2013-01-01to2013-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" unitRef="USD" decimals="0">-36103</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:LiabilitiesFairValueAdjustment contextRef="From2013-01-01to2013-12-31_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember_us-gaap_FairValueInputsLevel3Member" unitRef="USD" decimals="0">-87755</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:LiabilitiesFairValueAdjustment contextRef="From2014-01-01to2014-09-30_us-gaap_FairValueInputsLevel1Member_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" unitRef="USD" decimals="0">-115881</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:LiabilitiesFairValueAdjustment contextRef="From2014-01-01to2014-09-30_us-gaap_FairValueInputsLevel3Member_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" unitRef="USD" decimals="0">0</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:LiabilitiesFairValueAdjustment contextRef="From2014-01-01to2014-09-30_us-gaap_FairValueInputsLevel2Member_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" unitRef="USD" decimals="0">0</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:LiabilitiesFairValueAdjustment contextRef="From2013-01-01to2013-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" unitRef="USD" decimals="0">0</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2014-07-01to2014-09-30_us-gaap_StockOptionMember" unitRef="Shares" decimals="INF">334647</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2013-07-01to2013-09-30_us-gaap_StockOptionMember" unitRef="Shares" decimals="INF">430132</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2014-01-01to2014-09-30_us-gaap_StockOptionMember" unitRef="Shares" decimals="INF">398922</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2013-01-01to2013-09-30_us-gaap_StockOptionMember" unitRef="Shares" decimals="INF">460587</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2014-07-01to2014-09-30_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">417418</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2013-07-01to2013-09-30_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">426744</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2014-01-01to2014-09-30_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">418226</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2013-01-01to2013-09-30_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">432280</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2014-11-04" unitRef="Shares" decimals="INF">12904590</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:SalesRevenueGoodsNet contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">8139382</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet contextRef="From2014-07-01to2014-09-30" unitRef="USD" decimals="0">2042642</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet contextRef="From2013-07-01to2013-09-30" unitRef="USD" decimals="0">2724711</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet contextRef="From2013-01-01to2013-09-30" unitRef="USD" decimals="0">7169142</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:RoyaltyRevenue contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">85905</us-gaap:RoyaltyRevenue>
    <us-gaap:RoyaltyRevenue contextRef="From2014-07-01to2014-09-30" unitRef="USD" decimals="0">22778</us-gaap:RoyaltyRevenue>
    <us-gaap:RoyaltyRevenue contextRef="From2013-07-01to2013-09-30" unitRef="USD" decimals="0">25237</us-gaap:RoyaltyRevenue>
    <us-gaap:RoyaltyRevenue contextRef="From2013-01-01to2013-09-30" unitRef="USD" decimals="0">91761</us-gaap:RoyaltyRevenue>
    <us-gaap:OtherSalesRevenueNet contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">30133</us-gaap:OtherSalesRevenueNet>
    <us-gaap:OtherSalesRevenueNet contextRef="From2014-07-01to2014-09-30" unitRef="USD" decimals="0">10366</us-gaap:OtherSalesRevenueNet>
    <us-gaap:OtherSalesRevenueNet contextRef="From2013-07-01to2013-09-30" unitRef="USD" decimals="0">9391</us-gaap:OtherSalesRevenueNet>
    <us-gaap:OtherSalesRevenueNet contextRef="From2013-01-01to2013-09-30" unitRef="USD" decimals="0">34732</us-gaap:OtherSalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">8255420</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2014-07-01to2014-09-30" unitRef="USD" decimals="0">2075786</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2013-07-01to2013-09-30" unitRef="USD" decimals="0">2759339</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2013-01-01to2013-09-30" unitRef="USD" decimals="0">7295635</us-gaap:SalesRevenueNet>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">3707632</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="From2014-07-01to2014-09-30" unitRef="USD" decimals="0">1157590</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="From2013-07-01to2013-09-30" unitRef="USD" decimals="0">1136350</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="From2013-01-01to2013-09-30" unitRef="USD" decimals="0">3138916</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">4547788</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="From2014-07-01to2014-09-30" unitRef="USD" decimals="0">918196</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="From2013-07-01to2013-09-30" unitRef="USD" decimals="0">1622989</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="From2013-01-01to2013-09-30" unitRef="USD" decimals="0">4156719</us-gaap:GrossProfit>
    <us-gaap:SellingAndMarketingExpense contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">1866566</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="From2014-07-01to2014-09-30" unitRef="USD" decimals="0">606464</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="From2013-07-01to2013-09-30" unitRef="USD" decimals="0">1244907</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="From2013-01-01to2013-09-30" unitRef="USD" decimals="0">1856106</us-gaap:SellingAndMarketingExpense>
    <us-gaap:LaborAndRelatedExpense contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">1878042</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense contextRef="From2014-07-01to2014-09-30" unitRef="USD" decimals="0">629661</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense contextRef="From2013-07-01to2013-09-30" unitRef="USD" decimals="0">577302</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense contextRef="From2013-01-01to2013-09-30" unitRef="USD" decimals="0">1622635</us-gaap:LaborAndRelatedExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">799540</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2014-07-01to2014-09-30" unitRef="USD" decimals="0">285787</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2013-07-01to2013-09-30" unitRef="USD" decimals="0">425683</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2013-01-01to2013-09-30" unitRef="USD" decimals="0">1294841</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:DepreciationAndAmortization contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">58727</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="From2014-07-01to2014-09-30" unitRef="USD" decimals="0">19583</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="From2013-07-01to2013-09-30" unitRef="USD" decimals="0">18916</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="From2013-01-01to2013-09-30" unitRef="USD" decimals="0">71271</us-gaap:DepreciationAndAmortization>
    <us-gaap:OperatingExpenses contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">4602875</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2014-07-01to2014-09-30" unitRef="USD" decimals="0">1541495</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2013-07-01to2013-09-30" unitRef="USD" decimals="0">2266808</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2013-01-01to2013-09-30" unitRef="USD" decimals="0">4844853</us-gaap:OperatingExpenses>
    <us-gaap:IncomeLossFromContinuingOperations contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">-55087</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations contextRef="From2014-07-01to2014-09-30" unitRef="USD" decimals="0">-623299</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations contextRef="From2013-07-01to2013-09-30" unitRef="USD" decimals="0">-643819</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations contextRef="From2013-01-01to2013-09-30" unitRef="USD" decimals="0">-688134</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">294536</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="From2014-07-01to2014-09-30" unitRef="USD" decimals="0">59694</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="From2013-07-01to2013-09-30" unitRef="USD" decimals="0">80724</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="From2013-01-01to2013-09-30" unitRef="USD" decimals="0">-121153</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:InterestAndDebtExpense contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">45498</us-gaap:InterestAndDebtExpense>
    <us-gaap:InterestAndDebtExpense contextRef="From2014-07-01to2014-09-30" unitRef="USD" decimals="0">14671</us-gaap:InterestAndDebtExpense>
    <us-gaap:InterestAndDebtExpense contextRef="From2013-07-01to2013-09-30" unitRef="USD" decimals="0">7889</us-gaap:InterestAndDebtExpense>
    <us-gaap:InterestAndDebtExpense contextRef="From2013-01-01to2013-09-30" unitRef="USD" decimals="0">63223</us-gaap:InterestAndDebtExpense>
    <us-gaap:InterestExpense contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">33338</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="From2014-07-01to2014-09-30" unitRef="USD" decimals="0">12653</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="From2013-07-01to2013-09-30" unitRef="USD" decimals="0">10615</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="From2013-01-01to2013-09-30" unitRef="USD" decimals="0">23200</us-gaap:InterestExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">160613</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="From2014-07-01to2014-09-30" unitRef="USD" decimals="0">-590929</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="From2013-07-01to2013-09-30" unitRef="USD" decimals="0">-581599</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="From2013-01-01to2013-09-30" unitRef="USD" decimals="0">-895710</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">63264</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2014-07-01to2014-09-30" unitRef="USD" decimals="0">-609073</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2013-07-01to2013-09-30" unitRef="USD" decimals="0">-655207</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2013-01-01to2013-09-30" unitRef="USD" decimals="0">-785104</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic contextRef="From2014-01-01to2014-09-30" unitRef="USDPShares" decimals="INF">0.00</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic contextRef="From2014-07-01to2014-09-30" unitRef="USDPShares" decimals="INF">-0.05</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic contextRef="From2013-07-01to2013-09-30" unitRef="USDPShares" decimals="INF">-0.05</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic contextRef="From2013-01-01to2013-09-30" unitRef="USDPShares" decimals="INF">-0.06</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted contextRef="From2014-01-01to2014-09-30" unitRef="USDPShares" decimals="INF">0.00</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted contextRef="From2014-07-01to2014-09-30" unitRef="USDPShares" decimals="INF">-0.05</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted contextRef="From2013-07-01to2013-09-30" unitRef="USDPShares" decimals="INF">-0.05</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted contextRef="From2013-01-01to2013-09-30" unitRef="USDPShares" decimals="INF">-0.06</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="From2014-01-01to2014-09-30" unitRef="Shares" decimals="INF">12886216</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="From2014-07-01to2014-09-30" unitRef="Shares" decimals="INF">12892515</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="From2013-07-01to2013-09-30" unitRef="Shares" decimals="INF">12878216</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="From2013-01-01to2013-09-30" unitRef="Shares" decimals="INF">12730371</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="From2014-01-01to2014-09-30" unitRef="Shares" decimals="INF">13703364</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="From2014-07-01to2014-09-30" unitRef="Shares" decimals="INF">12892515</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="From2013-07-01to2013-09-30" unitRef="Shares" decimals="INF">12878216</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="From2013-01-01to2013-09-30" unitRef="Shares" decimals="INF">12730371</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:DepreciationAmortizationAndAccretionNet contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">58727</us-gaap:DepreciationAmortizationAndAccretionNet>
    <us-gaap:DepreciationAmortizationAndAccretionNet contextRef="From2013-01-01to2013-09-30" unitRef="USD" decimals="0">70203</us-gaap:DepreciationAmortizationAndAccretionNet>
    <us-gaap:ShareBasedCompensation contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">43837</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2013-01-01to2013-09-30" unitRef="USD" decimals="0">303797</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInAssetsHeldForSale contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">-21926</us-gaap:IncreaseDecreaseInAssetsHeldForSale>
    <us-gaap:IncreaseDecreaseInAssetsHeldForSale contextRef="From2013-01-01to2013-09-30" unitRef="USD" decimals="0">-109791</us-gaap:IncreaseDecreaseInAssetsHeldForSale>
    <us-gaap:IncreaseDecreaseInDerivativeAssetsAndLiabilities contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">-244570</us-gaap:IncreaseDecreaseInDerivativeAssetsAndLiabilities>
    <us-gaap:IncreaseDecreaseInDerivativeAssetsAndLiabilities contextRef="From2013-01-01to2013-09-30" unitRef="USD" decimals="0">71398</us-gaap:IncreaseDecreaseInDerivativeAssetsAndLiabilities>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">77958</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="From2013-01-01to2013-09-30" unitRef="USD" decimals="0">-128536</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">504598</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="From2013-01-01to2013-09-30" unitRef="USD" decimals="0">-718019</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">45448</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable contextRef="From2013-01-01to2013-09-30" unitRef="USD" decimals="0">0</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInNotesReceivables contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">7199</us-gaap:IncreaseDecreaseInNotesReceivables>
    <us-gaap:IncreaseDecreaseInNotesReceivables contextRef="From2013-01-01to2013-09-30" unitRef="USD" decimals="0">-1066</us-gaap:IncreaseDecreaseInNotesReceivables>
    <us-gaap:IncreaseDecreaseInInventories contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">-660543</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="From2013-01-01to2013-09-30" unitRef="USD" decimals="0">-332813</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">-19920</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="From2013-01-01to2013-09-30" unitRef="USD" decimals="0">-581336</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInDepositOtherAssets contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">8280</us-gaap:IncreaseDecreaseInDepositOtherAssets>
    <us-gaap:IncreaseDecreaseInDepositOtherAssets contextRef="From2013-01-01to2013-09-30" unitRef="USD" decimals="0">-16386</us-gaap:IncreaseDecreaseInDepositOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">39787</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade contextRef="From2013-01-01to2013-09-30" unitRef="USD" decimals="0">591743</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">50000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="From2013-01-01to2013-09-30" unitRef="USD" decimals="0">-95375</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">-82213</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="From2013-01-01to2013-09-30" unitRef="USD" decimals="0">266032</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">-130074</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2013-01-01to2013-09-30" unitRef="USD" decimals="0">-1460878</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">23105</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2013-01-01to2013-09-30" unitRef="USD" decimals="0">119194</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSalesOfAssetsInvestingActivities contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">87843</us-gaap:ProceedsFromSalesOfAssetsInvestingActivities>
    <us-gaap:ProceedsFromSalesOfAssetsInvestingActivities contextRef="From2013-01-01to2013-09-30" unitRef="USD" decimals="0">26919</us-gaap:ProceedsFromSalesOfAssetsInvestingActivities>
    <us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">0</us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments>
    <us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments contextRef="From2013-01-01to2013-09-30" unitRef="USD" decimals="0">965886</us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">64738</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2013-01-01to2013-09-30" unitRef="USD" decimals="0">873611</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromNotesPayable contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">0</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable contextRef="From2013-01-01to2013-09-30" unitRef="USD" decimals="0">25101</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">3539</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable contextRef="From2013-01-01to2013-09-30" unitRef="USD" decimals="0">3482</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:ProceedsFromLinesOfCredit contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">411000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit contextRef="From2013-01-01to2013-09-30" unitRef="USD" decimals="0">0</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:RepaymentsOfLinesOfCredit contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">11136</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:RepaymentsOfLinesOfCredit contextRef="From2013-01-01to2013-09-30" unitRef="USD" decimals="0">50000</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:ProceedsFromWarrantExercises contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises contextRef="From2013-01-01to2013-09-30" unitRef="USD" decimals="0">334</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">396325</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2013-01-01to2013-09-30" unitRef="USD" decimals="0">-28047</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">330989</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="From2013-01-01to2013-09-30" unitRef="USD" decimals="0">-615314</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:InterestPaid contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">40590</us-gaap:InterestPaid>
    <us-gaap:InterestPaid contextRef="From2013-01-01to2013-09-30" unitRef="USD" decimals="0">37049</us-gaap:InterestPaid>
    <us-gaap:IncomeTaxesPaid contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">8730</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid contextRef="From2013-01-01to2013-09-30" unitRef="USD" decimals="0">6863</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">0</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities contextRef="From2013-01-01to2013-09-30" unitRef="USD" decimals="0">87755</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <ifit:DecreaseInDeferredTaxAssetDueToWarrantExercise contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">0</ifit:DecreaseInDeferredTaxAssetDueToWarrantExercise>
    <ifit:DecreaseInDeferredTaxAssetDueToWarrantExercise contextRef="From2013-01-01to2013-09-30" unitRef="USD" decimals="0">33355</ifit:DecreaseInDeferredTaxAssetDueToWarrantExercise>
    <ifit:CashlessExerciseOfOptions contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">0</ifit:CashlessExerciseOfOptions>
    <ifit:CashlessExerciseOfOptions contextRef="From2013-01-01to2013-09-30" unitRef="USD" decimals="0">600</ifit:CashlessExerciseOfOptions>
    <ifit:CashlessExerciseOfWarrants contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">0</ifit:CashlessExerciseOfWarrants>
    <ifit:CashlessExerciseOfWarrants contextRef="From2013-01-01to2013-09-30" unitRef="USD" decimals="0">1555</ifit:CashlessExerciseOfWarrants>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2014-01-01to2014-09-30">&lt;p style="margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;Note 1 - Summary of Significant Accounting Policies&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Organization and Nature of Business, and Basis&#13;of Presentation&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;iSatori, Inc. (the &amp;#147;Company&amp;#148;)&#13;was incorporated under the laws of the state of Delaware on June 29, 2012. The trading symbol of the Company on OTCQB is &amp;#147;IFIT&amp;#148;.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The Company is engaged in researching,&#13;designing, developing, contracting for the manufacture, marketing, selling and distributing of various branded nutritional and&#13;dietary supplement products for the general nutrition market. The &amp;#147;general nutrition market&amp;#148; may include such activities&#13;as body-building, weight-training, physique enhancement (e.g., increase of lean body mass and decrease in fat mass) and enhanced&#13;athletic performance through increased strength and/or endurance and proper nutrition.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The Company engages in funding&#13;clinical studies with the objective of discovering and/or validating claims of new, efficacious and safe products for the Company&amp;#146;s&#13;relevant market as well as providing necessary and appropriate substantiation for any claims which the Company may use in its&#13;marketing and advertising. The Company markets products which are under its control and which are in some way proprietary to the&#13;Company. Some of the Company&amp;#146;s products are the subject of patents, service marks and or trademarks owned by the Company.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Unaudited Interim Financial&#13;Information&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The accompanying interim condensed&#13;financial statements have been prepared in accordance with our accounting practices described in our audited financial statements&#13;for the year ended December 31, 2013, and are unaudited. These unaudited interim condensed financial statements should be read&#13;in conjunction with the audited financial statements and accompanying notes for the year ended December 31, 2013. The accompanying&#13;interim condensed financial statements are presented in accordance with the rules and regulations of the Securities and Exchange&#13;Commission and, accordingly, do not include all the disclosures required by generally accepted accounting principles in the United&#13;States (&amp;#147;U.S. GAAP&amp;#148;) with respect to annual financial statements. In the opinion of management, all adjustments, consisting&#13;of normal recurring accruals that are considered necessary for a fair presentation of the interim condensed financial information,&#13;have been included. However, operating results for the periods presented are not necessarily indicative of the results that may&#13;be expected for a full year.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Financial Instruments&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The Company considers all highly&#13;liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents. Accordingly, cash&#13;and cash equivalents consist of petty cash, checking accounts and money market funds.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Fair Value Measurements&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;ASC 820-10 establishes a framework&#13;for measuring the fair value of assets and liabilities and requires additional disclosure about fair value measurements. ASC 820-10&#13;defines fair value as the price that would be received to sell an asset or paid to transfer a liability in the principal (or most&#13;advantageous market) for the asset or liability in an orderly transaction between market participants at the measurement date.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The Company has a number of financial&#13;instruments, including cash, cash equivalents, receivables, inventory, payables and debt obligations. The carrying amount of cash&#13;and cash equivalents, receivables, accounts payable, accrued expenses and notes payable approximates their fair value because&#13;of the short maturity of these instruments. As further described in Note 7, the Company has issued warrants which are measured&#13;at fair value on a recurring basis and result in a long-term derivative liability on the balance sheet. The actual and estimated&#13;fair values, respectively, of the Company&amp;#146;s financial instruments are as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="margin-top: 0px; font-size: 9pt; width: 100%"&gt;&#13;&lt;tr style="font-size: 1pt"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 65px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 66px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 65px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 65px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="5" style="border-bottom: #000000 1px solid; vertical-align: bottom; font-size: 8.5pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;September&#13;    30, 2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; font-size: 8.5pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="5" style="border-bottom: #000000 1px solid; vertical-align: bottom; font-size: 8.5pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;December&#13;    31, 2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: #000000 1px solid"&gt;&lt;p style="font-size: 8.5pt; text-align: center; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Carrying&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;        &lt;p style="font-size: 8.5pt; text-align: center; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: #000000 1px solid; font-size: 8.5pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Fair&#13;    Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: #000000 1px solid"&gt;&lt;p style="font-size: 8.5pt; text-align: center; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Carrying&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;        &lt;p style="font-size: 8.5pt; text-align: center; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: #000000 1px solid; font-size: 8.5pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Fair&#13;    Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: #ebebff"&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Cash and cash equivalents&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,153,865&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,153,865&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;822,876&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;822,876&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Receivables&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,893,580&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,893,580&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,398,178&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,398,178&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: #ebebff"&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Accounts Payable&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,276,642&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,276,642&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,248,490&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,248,490&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Derivative Liability&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;226,445&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;226,445&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;471,015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;471,015&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Trade Receivables and Credit&#13;Policy&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Trade receivables are uncollateralized&#13;customer obligations due under normal trade terms requiring payment generally within 10-60 days from the invoice date. Accounts&#13;are considered delinquent when outstanding for more than 7 days past due date. The Company does not have a policy of accruing&#13;interest on past due accounts. Payments on trade receivables are applied as instructed per the customer, or to the earliest unpaid&#13;invoices. The allowance for doubtful accounts represents an estimate of amounts considered uncollectible and is determined based&#13;on management&amp;#146;s historical collection experience, adverse situations that may affect the customer&amp;#146;s ability to repay,&#13;and prevailing economic conditions. Specific accounts deemed uncollectible are written off periodically with subsequent receipts&#13;on previously written off accounts credited to bad debt expense. The allowance for doubtful accounts is $0 for each of the periods&#13;ended September 30, 2014 and December 31, 2013. Receivables at each of the below respective periods consisted of the following:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; margin-top: 0px; font-size: 9pt"&gt;&#13;&lt;tr style="font-size: 1pt"&gt;&#13;    &lt;td style="width: 71%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: #000000 1px solid; vertical-align: bottom"&gt;&lt;p style="font-size: 8.5pt; text-align: center; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;September&#13;                                         30,&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;        &lt;p style="font-size: 8.5pt; text-align: center; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; font-size: 8.5pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: #000000 1px solid; vertical-align: bottom"&gt;&lt;p style="font-size: 8.5pt; text-align: center; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;December&#13;                                         31,&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;        &lt;p style="font-size: 8.5pt; text-align: center; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: #ebebff"&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Trade Receivables&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,834,174&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,323,522&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Other&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;59,406&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;74,656&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: #ebebff"&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Allowance for doubtful accounts&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 1px solid; vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 1px solid; vertical-align: top; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(0)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 1px solid; vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 1px solid; vertical-align: top; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(0)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Totals&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 3px double; vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 3px double; vertical-align: top; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,893,580&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 3px double; vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 3px double; vertical-align: top; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,398,178&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In addition, the Company has&#13;recorded an allowance for customer returns in the amount of approximately $85,000 and $70,000 at September 30, 2014 and December&#13;31, 2013, respectively, in accrued expenses.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Inventory Valuation&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Inventories of nutritional and&#13;dietary supplements are stated at lower of cost or market on a first-in, first-out (FIFO) basis as noted below:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; margin-top: 0px; font-size: 9pt"&gt;&#13;&lt;tr style="font-size: 1pt"&gt;&#13;    &lt;td style="width: 70%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: #000000 1px solid; vertical-align: bottom"&gt;&lt;p style="font-size: 8.5pt; text-align: center; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;September&#13;                                         30,&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;        &lt;p style="font-size: 8.5pt; text-align: center; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; font-size: 8.5pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: #000000 1px solid; vertical-align: bottom"&gt;&lt;p style="font-size: 8.5pt; text-align: center; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;December&#13;                                         31,&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;        &lt;p style="font-size: 8.5pt; text-align: center; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: #ebebff"&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Labels and packaging&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;170,189&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;120,057&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Raw materials&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;284,560&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;207,320&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: #ebebff"&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Finished goods&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 1px solid; vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 1px solid; vertical-align: top; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,191,558&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 1px solid; vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 1px solid; vertical-align: top; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,658,387&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Totals&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 3px double; vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 3px double; vertical-align: top; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,646,307&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 3px double; vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 3px double; vertical-align: top; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,985,764&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Note Receivable&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The predecessor company disposed&#13;of a dormant product line of vitamins in December 2010. As part of the consideration in this divestiture, the Company received&#13;from the purchaser of this product line an unsecured note in the amount of $170,000. The original note was due to be repaid on&#13;or before March 2014, where interest accrued principally at an annual rate of 5%, based upon the initial $170,000 principal and&#13;was payable monthly. As of March 31, 2013, the note was novated and a new promissory note was issued to reflect a modification&#13;in the payment terms, which includes no interest. The total note receivable balance at September 30, 2014 was $85,528, and is&#13;due to be repaid in monthly increments through May 1, 2017.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Revenue Recognition&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The Company operates predominantly&#13;as a distributor of its dietary supplement products through traditional large retailers, wholesale distributors, and electronic&#13;intermediaries. Revenue from product sales is recognized upon transfer of title of the Company&amp;#146;s product to its customers.&#13;Net sales represent product sales less actual returns, trade allowances, discounts, and product promotions. Sales to direct customers&#13;have an unconditional money back guarantee for thirty to ninety days after the date of purchase. Sales to a select number of the&#13;retail customers carry a &amp;#147;Sale or Return&amp;#148; Purchase agreement per contract, where if minimum sales thresholds are not&#13;met within required timeframe, the inventory will be returned to the Company for full credit. Other retail customers receive a&#13;percentage discount from invoice to cover any customer returns or damages they may incur. Returns, trade allowances, discounts,&#13;and product promotions were $840,670 and $484,296 for the three month period ended September 30, 2014 and 2013, respectively.&#13;Returns, trade allowances, discounts, and product promotions were $2,200,761 and $1,492,824 for the nine month period ended September&#13;30, 2014 and 2013, respectively.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In addition, the Company provides&#13;allowances for sales returns based upon estimated and known returns. Product returns are recorded as a reduction of net revenues&#13;and as a reduction of the accounts receivable balance.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The Company receives other revenues&#13;which include but are not limited to shipping and handling charges billed to customers.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The Company has recorded $210,002&#13;as of September 30, 2014 in deferred revenue as a liability pertaining to inventory sold under consignment terms, even though&#13;it has already been paid for by the customer.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Cost of Sales&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The Company purchases its products&#13;directly from third party manufacturers. The Company&amp;#146;s cost of sales include product costs, including any associated materials&#13;used in production, cost of warehousing and distribution. Included in the cost of sales are transit freight and shipping and handling&#13;costs that are incurred by the Company.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Income Taxes&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The Company utilizes the asset&#13;and liability method of accounting for income taxes. Under this asset and liability method, deferred tax assets and liabilities&#13;are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying&#13;amounts of existing assets and liabilities, and their respective tax bases. Deferred tax assets and liabilities are measured using&#13;enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. See Note&#13;4, &amp;#147;Income Taxes&amp;#148;.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Since 2012 was the Company&amp;#146;s&#13;initial tax year, there are no prior federal or state tax returns subject to examination. Accordingly, the only taxable periods&#13;subject to examination by federal and state taxing authorities are the periods ended December 31, 2013 and 2012. Federal and state&#13;tax returns for the Company prior to the short form merger are open for the period ended December 31, 2011.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Leases&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The Company leases its headquarters&#13;facility, comprising approximately 10,044 square feet, in Golden (metropolitan Denver), Colorado. The total rent expense for each&#13;of the three month periods ended September 30, 2014 and 2013, was $20,716. The total rent expense for each of the nine month periods&#13;ended September 30, 2014 and 2013, was $62,147. The lease term expires January 31, 2017 and requires equal monthly payments over&#13;the remaining term. Future payments under the lease total $193,347. The Company also leases miscellaneous office and warehouse&#13;equipment. In most cases, management expects that in the normal course of business these leases will be renewed or replaced by&#13;other leases as applicable.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Marketing&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The Company expenses all production&#13;costs related to advertising costs as they are incurred, including print, digital, and television when the advertisement has been&#13;broadcast or otherwise finished and or distributed. The Company records website costs related to its direct-to-consumer advertisements&#13;in accordance with FASB ASC 340-20 &amp;#147;Capitalized Advertising Costs&amp;#148;. In accordance with FASB ASC 340-20, direct response&#13;advertising costs incurred should be reported as assets and should be amortized over the estimated period of the benefits, based&#13;on the proportion of current period revenue from the advertisements to probable future revenue. As of September 30, 2014 and December&#13;31, 2013, the Company had deferred $0 and $7,651 respectively, related to such advertising costs. This amount was included in&#13;Deposits and other assets and amortized over a one year period, the estimated time frame to which the existing commercial was&#13;used. For the three month period ended September 30, 2014 and 2013, marketing expenses totaled $310,580 and $1,005,858, respectively.&#13;For the nine month period ended September 30, 2014 and 2013, marketing expenses totaled $1,252,698 and $1,330,788, respectively.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Research and Development Costs&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Research and development costs,&#13;which includes the funding of clinical research studies, as well as creation and development of new products, are expensed when&#13;incurred. Research and development costs of $57,002 and $68,071 for the three month period ended September 30, 2014 and 2013,&#13;respectively, are included in selling and marketing expense. Research and development costs of $67,907 and $155,836 for the nine&#13;month period ended September 30, 2014 and 2013, respectively, are included in selling and marketing expense.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Distribution, Shipping and&#13;Handling Costs&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Shipping costs on purchases and&#13;shipping and handling fees related to sales charged to customers are both included in cost of sales. As mentioned in Revenue Recognition,&#13;shipping and handling revenue billed customers are reflected in other revenues.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Concentration of Credit Risk&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Financial instruments that potentially&#13;subject the Company to concentration of credit risk consist principally of trade accounts receivables. Concentrations of credit&#13;with respect to trade receivables are limited due to the large number of customers comprising the Company&amp;#146;s customer bases&#13;and their dispersion across different geographic locations.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The Company maintains cash balances&#13;at one financial institution located in Colorado and one in California. Accounts at these institutions are insured by the Federal&#13;Deposit Insurance Corporation (FDIC) up to $250,000 per account. At times during the year, the Company&amp;#146;s bank balances have&#13;exceeded the FDIC limit. Management believes the risk of loss at such institutions to be minimal.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;During the nine month period&#13;ended September 30, 2014, sales to three customers made up 60% of total product revenue, with each customer representing greater&#13;than 10% of product revenue on an individual basis. These customers&amp;#146; combined accounts receivable balances were 56% of total&#13;accounts receivable at September 30, 2014. During the nine month period ended September 30, 2013, sales to three customers made&#13;up 56% of total product revenue, with each customer representing greater than 10% of product revenue on an individual basis. These&#13;customers&amp;#146; combined accounts receivable balances were 65% of total accounts receivable as of September 30, 2013. During&#13;the nine month period ended September 30, 2014, purchases from four vendors made up 70% of total inventory purchases. These vendors&amp;#146;&#13;combined accounts payable balances were 58% of total accounts payable as of September 30, 2014. During the nine month period ended&#13;September 30, 2013, purchases from two vendors made up 73% of total inventory purchases. These vendors&amp;#146; combined accounts&#13;payable balances were 43% of total accounts payable as of September 30, 2013.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Use of Estimates&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The preparation of the financial&#13;statements in conformity with accounting principles generally accepted in the United States of America requires management to&#13;make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements&#13;and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&#13;Significant estimates include but are not limited to the fair value determination of derivative instruments, the valuation allowance&#13;with respect to estimated utilization of net operating losses, estimated allowances for sales returns and collectability of trade&#13;receivables.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Earnings (Loss) Per Share&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Net earnings (loss) per share&#13;is computed by dividing net income (loss) less preferred dividends for the period by the weighted average number of shares of&#13;common stock outstanding during each period. Diluted earnings (loss) per share is computed by dividing net income (loss) less&#13;preferred dividends for the period by the weighted average number of shares of common stock, common stock equivalents and potentially&#13;dilutive securities outstanding during each period.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Since the Company reflected a&#13;net loss for the three month period ended September 30, 2014 and the three and nine month periods ended September 30, 2013, the&#13;effect of considering any common stock equivalents, if exercisable, would have been anti-dilutive.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The Company has the following&#13;common stock equivalents as of September 30, 2014 and 2013:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="margin-top: 0px; font-size: 9pt; width: 100%"&gt;&#13;&lt;tr style="font-size: 1pt"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 18px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 73px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 7px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 73px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 5px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 73px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 7px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 73px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="vertical-align: bottom"&gt;&lt;p style="font-size: 8.5pt; text-align: center; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Three&#13;                                         Months Ended&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;        &lt;p style="font-size: 8.5pt; text-align: center; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;September&#13;        30,&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; font-size: 8.5pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="vertical-align: bottom"&gt;&lt;p style="font-size: 8.5pt; text-align: center; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Nine&#13;                                         Months Ended&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;        &lt;p style="font-size: 8.5pt; text-align: center; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;September&#13;        30,&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font-size: 8.5pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-size: 8.5pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 1px solid; font-size: 8.5pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-size: 8.5pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 1px solid; font-size: 8.5pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-size: 8.5pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 1px solid; font-size: 8.5pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-size: 8.5pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 1px solid; font-size: 8.5pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #ebebff"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Basic weighted average common shares outstanding&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-size: 8.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;12,892,515&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;12,878,216&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;12,886,216&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;12,730,371&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Stock options (exercise price &amp;#150; $0.573-$2.50/share)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;334,647&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;430,132&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;398,922&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;460,587&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #ebebff"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Warrants (exercise price &amp;#150; $0.001-$2.25/share)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;417,418&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;426,744&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;418,226&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;432,280&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total common stock equivalents&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;13,644,580&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;13,735,092&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;13,703,364&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;13,623,238&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:LossContingencyDisclosures contextRef="From2014-01-01to2014-09-30">&lt;p style="margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;Note 2 - Contingencies&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In accordance with the standards&#13;on contingencies, the Company accrues a loss contingency if it is probable and can reasonably be estimated or a liability has&#13;been incurred at the date of the financial statements. If both of these conditions are not met, or if an exposure to loss exists&#13;in excess of the amount accrued, disclosure of the contingency shall be made when there is at least a reasonable possibility that&#13;a loss or an additional loss may have been incurred. The Company is exposed to legal claims encountered in the normal course of&#13;business. See Note 3, &amp;#147;Litigation&amp;#148;. Management believes that the ultimate resolution of these matters will not have&#13;a material adverse effect on the operating results or the financial position of the Company.&lt;/font&gt;&lt;/p&gt;</us-gaap:LossContingencyDisclosures>
    <us-gaap:LegalMattersAndContingenciesTextBlock contextRef="From2014-01-01to2014-09-30">&lt;p style="text-align: justify; text-indent: 0; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;Note&#13;3 - Litigation&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The Company is engaged in various&#13;legal actions, claims and proceedings arising in the normal course of business, including claims related to breach of contracts,&#13;product liabilities and intellectual property matters resulting from the Company&amp;#146;s business activities. As with most actions&#13;such as these, an estimation of any possible and/or ultimate liability cannot always be determined. The following summaries highlight&#13;the current status of certain material commercial litigation in which the Company is involved.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;On May 17, 2013 and on January&#13;31, 2014 the Company received demand letters from the Environmental Research Corporation, &amp;#147;ERC&amp;#148; requesting substantiation&#13;of compliance with the State of California&amp;#146;s Proposition 65 regulations for ten of its products. In October, while the Company&#13;was awaiting the results of the compliance testing, ERC contacted the Company again requesting settlement to their initial demand&#13;letter. And in February 2014, before compliance testing or any other demand letter validation was completed, ERC contacted the&#13;Company again requesting settlement to their second demand letter. After many discussions with ERC, a lawsuit was filed by ERC&#13;for the non-compliance issues with the State of California&amp;#146; Proposition 65 regulations. Along with the company&amp;#146;s California&#13;counsel the company has begun the process of discovery from both sides. The Company continues to remain in communication with&#13;ERC and their counsel with the intent to settle the mutual disputes. The Company believes that there is a reasonable possibility,&#13;as defined by FASB ASC 450-20, of an unfavorable outcome. However, the range of any possible loss cannot be reasonably estimated&#13;as of the date of the financial statements.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;On March 24, 2014 the Company&#13;received a summons in a civil action filed by Wise Sports Nutrition, LLC claiming alleged trademark infringement for iSatori&amp;#146;s&#13;Garcinia Trim product. Company counsel has made contact with the plaintiff&amp;#146;s attorney and filed a response to the alleged&#13;trademark infringement with the Company&amp;#146;s counterclaims. The Company believes the counterclaims have strong merit and are&#13;pursuing their defense. Both parties have prepared responses and presented them to the court. The case has currently been stayed&#13;pending a ruling on the motion made by the Company to stay the case. The Company believes that it is too early in the proceedings&#13;to make a determination of either a favorable or unfavorable outcome. Therefore, no range of any possible gain or loss can be&#13;reasonably estimated as of the date of the financial statements.&lt;/font&gt;&lt;/p&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2014-01-01to2014-09-30">&lt;p style="text-align: justify; text-indent: 0; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;Note&#13;4 - Income Taxes&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;For the three months ended September&#13;30, 2014 and 2013, the Company recognized income tax expense of $18,144, and expense of $73,608, respectively.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;For the nine months ended September&#13;30, 2014, the Company recognized income tax expense of $97,349, and for the nine months ended September 30, 2013, the Company&#13;recognized an income tax benefit of $110,606.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The difference between the nine&#13;months ended September 30, 2014 effective rate of 48.64% and the Federal statutory rate of 35.0% is primarily due to state and&#13;foreign income taxes (net of federal benefit), change in the valuation allowance, and an adjustment to the income tax receivable.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;At September 30, 2014 management&#13;believes there are no uncertain tax positions.&lt;/font&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2014-01-01to2014-09-30">&lt;p style="text-align: justify; text-indent: 0; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;Note&#13;5- Stockholders&amp;#146; Equity&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;At September 30, 2014, there&#13;were 12,896,852 shares of common stock, par value $.01 per share, outstanding for the Company.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The Company issued warrants, now totaling 420,549&#13;shares, to purchase 3% of fully diluted shares of the common stock of the Company to Breakwater Structured Growth Opportunity&#13;Fund, L.P., with an imputed exercise price equal to approximately one-hundredth of a dollar in connection with a $1.025 million&#13;subordinated mezzanine loan arrangement. These warrants are fully vested and expire on June 15, 2016. The Company used a lattice&#13;model in developing a fair value for the Breakwater warrant obligation at September 30, 2014, using a quoted stock value of $.55&#13;per share, which represents a discount of 50% from the closing stock price. This reduction was based on the application of a discount&#13;for lack of liquidity. Other assumptions used in the above valuations include (a) risk-free interest rate of .58% based on duration,&#13;(b) weighted average expected term years of 1.79 (c) weighted average expected stock volatility of 37.46% (e) expected dividends&#13;of 0%, (f) stock price movements ranging from 1.05332062 to .94937855 and (g) risk neutral probabilities ranging from .48808915&#13;to .51191085.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The warrant valuation resulted&#13;in income of $52,568 in the Statement of Operations for the three month period ended September 30, 2014, and income of $41,501&#13;in the Statement of Operations for the three month period ended September 30, 2013. For the nine month period ended September&#13;30, 2014, the valuation resulted in income of $244,570 in the Statement of Operations, and for the nine month period ended September&#13;30, 2013 the valuation resulted in expense of $71,398 in the Statement of Operations.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;On April 1, 2014, the Company&#13;issued 7,500 shares of its $.01 par value common stock to a business development consultant. The Company considered the fair value&#13;of the shares issued to be the most reliable measure of compensation to the consultant. At the time of the issuance, the Company&amp;#146;s&#13;stock price was $2.17 per share, and therefore the issuance resulted in $16,275 of share based compensation expense for the three&#13;and nine months ended September 30, 2014.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; text-indent: 0px; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;2012 Performance&#13;Incentive Plan&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;On September 27, 2012, the Company&amp;#146;s&#13;Board of Directors approved the 2012 Performance Incentive Plan (the Plan&amp;#148;). The Plan allows the Company to promote the&#13;success of the Corporation and to increase stockholder value by providing an additional means through the grant of awards to attract,&#13;motivate, retain and reward selected employees and other eligible persons. Any stock option granted in the form of an incentive&#13;stock option will be intended to comply with the&lt;font style="color: #00007f"&gt; &lt;/font&gt;requirements of Section 422 of the Code.&#13;Only stock options granted to employees qualify for incentive stock option treatment. A stock option may be exercised in whole&#13;or in installments, which may be cumulative. Shares of common stock purchased upon the exercise of a stock option must be paid&#13;for in full at the time of the exercise in cash or such other consideration determined by the compensation committee. Payment&#13;may include tendering shares of common stock or surrendering of a stock award, or a combination of methods.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The Plan is administered by the&#13;Plan Administrator, being the Board or one or more committees appointed by the Board or another committee (within its delegated&#13;authority) to administer all or certain aspects of this Plan. The Administrator has full and exclusive power within the limitations&#13;set forth in the Plan to make all decisions and determinations regarding the selection of participants and the granting of awards;&#13;establishing the terms and conditions relating to each award; adopting rules, regulations and guidelines; and interpreting the&#13;Plan.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;On January 2, 2014, the Company&#13;issued options to purchase 10,000 shares of the Company&amp;#146;s common stock to an employee with an exercise price of $2.50 per&#13;share and which contain three year vesting schedules of 1/3 each year through October 2016. These options are due to expire on&#13;October 15, 2023.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;On February 10, 2014, the Company&#13;issued options to purchase 6,000 shares of the Company&amp;#146;s common stock to an employee with an exercise price of $2.22 per&#13;share and which contain three year vesting schedules of 1/3 each year through February 2017. These options are due to expire on&#13;February 10, 2024.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The Company, in developing a&#13;fair value for the employee options used a current stock price of $1.11-1.25, which represents a discount of 50% from the quoted&#13;stock price for lack of marketability. Other assumptions used in the above valuations include (a) risk-free interest rate of 2.13-2.41%&#13;based on duration, (b) weighted average expected terms ranging from 6.08 to 6.33 years; (c) weighted average expected stock volatility&#13;of 35.22 % and (e) expected dividends of 0%.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The Company has recorded share&#13;based compensation expense due to option issuances under the Plan totaling $5,352 for the three months ended September 30, 2014,&#13;and has recorded share based compensation expense due to option issuances under the Plan totaling $17,474 for the nine months&#13;ended September 30, 2014.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;On July 10, 2014, the Company&#13;issued 5,603 shares of restricted stock to members of its board of directors. On September 23, 2014, the Company issued 4,098&#13;shares of restricted stock to a new member of its board of directors. The Company is amortizing total expense related to these&#13;issuances over the restriction period which is equivalent to the directors&amp;#146; one-year term. The Company has recorded share&#13;based compensation expense due to these issuances of $1,961 for the three months ended September 30, 2014, and share based compensation&#13;expense due to these and prior issuances of $10,087 for the nine months ended September 30, 2014.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2014-01-01to2014-09-30">&lt;p style="text-align: justify; text-indent: 0; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;Note&#13;6- Revolving Line of Credit and Related Interest&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The Company entered into a renewed&#13;and expanded Credit Agreement with Colorado Business Bank West of Denver, Colorado on August 27, 2014. Borrowings under this agreement&#13;are used to provide ongoing working capital and for other general corporate purposes of the Company.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The agreement provides a revolving&#13;commitment to the Company of $2,000,000. Amounts outstanding under the agreement are reflected in a promissory note with a principal&#13;balance of $2,000,000 and maturity date of November 16, 2015 (the &amp;#147;Promissory Note&amp;#148;). The principal balance on the&#13;Promissory Note bears interest at the one month USD LIBOR rate measured not more often than once per month (the &amp;#147;Index&amp;#148;).&#13;Interest on any unpaid balance under the promissory note will bear interest at the Index plus 3.75% with a minimum interest rate&#13;of 4.00% per annum, and is payable monthly. The agreement requires the Company to comply with certain affirmative covenants, including&#13;a minimum current ratio of 1.5 to 1, a maximum leverage ratio of 2 to 1, and minimum tangible equity capital of $2,750,000 through&#13;November 30, 2014, and $3,000,000 thereafter, as well as providing limitations on dividends, additional indebtedness, and certain&#13;other changes. As of September 30, 2014, the Company was in compliance with these covenants.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The Company&amp;#146;s prior line&#13;of credit with Colorado Business Bank West of Denver, Colorado provided a revolving commitment to the Company in the amount of&#13;$1,500,000 and was in effect since its inception on July 16, 2012 and subsequent renewal on October 16, 2013 through the date&#13;of the renewal and expansion on August 27, 2014. Other terms of the former credit agreement were the same as those of the renewed&#13;and expanded agreement described above.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The outstanding balance on the&#13;Company&amp;#146;s revolving line of credit as of September 30, 2014 and December 31, 2013 was $1,620,519 and $1,220,655, respectively.&lt;/font&gt;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:FairValueMeasurementInputsDisclosureTextBlock contextRef="From2014-01-01to2014-09-30">&lt;p style="text-align: justify; text-indent: 0; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;Note&#13;7 - Fair Value Measurements and Disclosures&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The Company follows ASC 820,&#13;Fair Value Measurements and Disclosures, which defines fair value, establishes a framework for using fair value to measure assets&#13;and liabilities, and expands disclosures about fair value measurements. The statement establishes a hierarchy for inputs used&#13;in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring&#13;that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing&#13;the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are&#13;inputs that reflect the Company&amp;#146;s assumptions of what market participants would use in pricing the asset or liability developed&#13;based on the best information available in the circumstances. The hierarchy is broken down into three levels based on the reliability&#13;of the inputs as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Level 1: Quoted prices are available&#13;in active markets for identical assets or liabilities.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Level 2: Quoted prices in active&#13;markets for similar assets and liabilities that are observable for the asset or liability; or&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Level 3: Unobservable pricing&#13;inputs that are generally less observable from objective sources, such as discounted cash flow models or valuations.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;ASC 820 requires financial assets&#13;and liabilities to be classified based on the lowest level of input that is significant to the fair value measurement. The Company&amp;#146;s&#13;assessment of the significance of a particular input to the fair value measurement requires judgment, and may affect the valuation&#13;of the fair value of assets and liabilities and their placement within the fair value hierarchy levels.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;For the purposes of marketable&#13;securities where there is an active market, the Company uses the quoted prices available for the identical asset or liability.&#13;As of September 30, 2014, the Company had $42,311 in assets held for sale valued using the Level 1 mark-to-market approach. As&#13;of December 31, 2013, the Company had $108,228 in assets held for sale valued using the Level 1 mark-to-market approach.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;For the purposes of the warrant&#13;derivative liability, the Company uses a lattice model and a combination of observable and unobservable inputs; therefore the&#13;fair value measurement of the liability is classified within Level 3 of the hierarchy. The inputs used in the fair value measurements&#13;categorized within Level 3 include the stock price at the valuation date, the exercise price of the warrant, the expected period&#13;of time the warrant will be outstanding, the annual volatility of the underlying stock price, the annual yield rate of quarterly&#13;dividends, and the risk free rate of interest relevant to the expected time period the warrant will be outstanding.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The following table represents&#13;the Company&amp;#146;s assets and liabilities that were accounted for at fair value on a recurring basis by level within the fair&#13;value hierarchy:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="margin-top: 0px; font-size: 9pt; width: 100%"&gt;&#13;&lt;tr style="font-size: 1pt"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 6px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 56px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 6px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 6px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 55px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 7px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 6px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 59px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 6px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 6px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 56px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 6px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 6px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 58px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 6px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 6px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 61px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="8" style="border-bottom: #000000 1px solid; vertical-align: bottom; font-size: 8.5pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;September&#13;    30, 2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; font-size: 8.5pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="8" style="border-bottom: #000000 1px solid; vertical-align: bottom; font-size: 8.5pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;December&#13;    31, 2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font-size: 8.5pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font-size: 8.5pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Level&#13;    1&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-size: 8.5pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font-size: 8.5pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Level&#13;    2&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-size: 8.5pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font-size: 8.5pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Level&#13;    3&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-size: 8.5pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font-size: 8.5pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Level&#13;    1&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-size: 8.5pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font-size: 8.5pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Level&#13;    2&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-size: 8.5pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font-size: 8.5pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Level&#13;    3&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font-size: 8.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-top: #000000 1px solid; font-size: 8.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-size: 8.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-top: #000000 1px solid; font-size: 8.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-size: 8.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-top: #000000 1px solid; font-size: 8.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-size: 8.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-top: #000000 1px solid; font-size: 8.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-size: 8.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-top: #000000 1px solid; font-size: 8.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-size: 8.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-top: #000000 1px solid; font-size: 8.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #ebebff"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Balance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 3px double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 3px double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;42,311&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 3px double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 3px double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 3px double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 3px double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;226,445&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 3px double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 3px double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;108,228&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 3px double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 3px double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 3px double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 3px double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;471,015&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Beginning of Period&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;108,228&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;471,015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;29,338&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;701,852&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #ebebff"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Deletions&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(115,881)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(36,103)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(87,755)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Revisions&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 1px solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 1px solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;49,964&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 1px solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 1px solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 1px solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 1px solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(244,570)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 1px solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 1px solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;114,993&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 1px solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 1px solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 1px solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 1px solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(143,082)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #ebebff"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;End of Period&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 3px double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 3px double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;42,311&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 3px double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 3px double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 3px double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 3px double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;226,445&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 3px double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 3px double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;108,228&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 3px double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 3px double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 3px double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 3px double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;471,015&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementInputsDisclosureTextBlock>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2014-01-01to2014-09-30">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; text-indent: 0; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;Note&#13;8 &amp;#150; Subsequent Events&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Effective November 1, the Company executed a 50-month&#13;lease of a 17,426 square foot building in Denver, CO to accommodate the growth in inventory and support warehouse operations.&#13;The warehouse operations will be moved prior to year end from its current location at the Golden, CO headquarters.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2014-01-01to2014-09-30">&lt;p style="margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Organization and Nature of Business, and Basis&#13;of Presentation&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;iSatori, Inc. (the &amp;#147;Company&amp;#148;)&#13;was incorporated under the laws of the state of Delaware on June 29, 2012. The trading symbol of the Company on OTCQB is &amp;#147;IFIT&amp;#148;.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The Company is engaged in researching,&#13;designing, developing, contracting for the manufacture, marketing, selling and distributing of various branded nutritional and&#13;dietary supplement products for the general nutrition market. The &amp;#147;general nutrition market&amp;#148; may include such activities&#13;as body-building, weight-training, physique enhancement (e.g., increase of lean body mass and decrease in fat mass) and enhanced&#13;athletic performance through increased strength and/or endurance and proper nutrition.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The Company engages in funding&#13;clinical studies with the objective of discovering and/or validating claims of new, efficacious and safe products for the Company&amp;#146;s&#13;relevant market as well as providing necessary and appropriate substantiation for any claims which the Company may use in its&#13;marketing and advertising. The Company markets products which are under its control and which are in some way proprietary to the&#13;Company. Some of the Company&amp;#146;s products are the subject of patents, service marks and or trademarks owned by the Company.&lt;/font&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2014-01-01to2014-09-30">&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Financial Instruments&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The Company considers all highly&#13;liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents. Accordingly, cash&#13;and cash equivalents consist of petty cash, checking accounts and money market funds.&lt;/font&gt;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2014-01-01to2014-09-30">&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Fair Value Measurements&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;ASC 820-10 establishes a framework&#13;for measuring the fair value of assets and liabilities and requires additional disclosure about fair value measurements. ASC 820-10&#13;defines fair value as the price that would be received to sell an asset or paid to transfer a liability in the principal (or most&#13;advantageous market) for the asset or liability in an orderly transaction between market participants at the measurement date.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The Company has a number of financial&#13;instruments, including cash, cash equivalents, receivables, inventory, payables and debt obligations. The carrying amount of cash&#13;and cash equivalents, receivables, accounts payable, accrued expenses and notes payable approximates their fair value because&#13;of the short maturity of these instruments. As further described in Note 7, the Company has issued warrants which are measured&#13;at fair value on a recurring basis and result in a long-term derivative liability on the balance sheet&lt;/font&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="From2014-01-01to2014-09-30">&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Trade Receivables and Credit&#13;Policy&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Trade receivables are uncollateralized&#13;customer obligations due under normal trade terms requiring payment generally within 10-60 days from the invoice date. Accounts&#13;are considered delinquent when outstanding for more than 7 days past due date. The Company does not have a policy of accruing&#13;interest on past due accounts. Payments on trade receivables are applied as instructed per the customer, or to the earliest unpaid&#13;invoices. The allowance for doubtful accounts represents an estimate of amounts considered uncollectible and is determined based&#13;on management&amp;#146;s historical collection experience, adverse situations that may affect the customer&amp;#146;s ability to repay,&#13;and prevailing economic conditions. Specific accounts deemed uncollectible are written off periodically with subsequent receipts&#13;on previously written off accounts credited to bad debt expense.&lt;/font&gt;&lt;/p&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:InventoryPolicyTextBlock contextRef="From2014-01-01to2014-09-30">&lt;p style="margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Inventory Valuation&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Inventories of nutritional and&#13;dietary supplements are stated at lower of cost or market on a first-in, first-out (FIFO) basis.&lt;/font&gt;&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="From2014-01-01to2014-09-30">&lt;p style="margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Revenue Recognition&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The Company operates predominantly&#13;as a distributor of its dietary supplement products through traditional large retailers, wholesale distributors, and electronic&#13;intermediaries. Revenue from product sales is recognized upon transfer of title of the Company&amp;#146;s product to its customers.&#13;Net sales represent product sales less actual returns, trade allowances, discounts, and product promotions. Sales to direct customers&#13;have an unconditional money back guarantee for thirty to ninety days after the date of purchase. Sales to a select number of the&#13;retail customers carry a &amp;#147;Sale or Return&amp;#148; Purchase agreement per contract, where if minimum sales thresholds are not&#13;met within required timeframe, the inventory will be returned to the Company for full credit. Other retail customers receive a&#13;percentage discount from invoice to cover any customer returns or damages they may incur. Returns, trade allowances, discounts,&#13;and product promotions were $840,670 and $484,296 for the three month period ended September 30, 2014 and 2013, respectively.&#13;Returns, trade allowances, discounts, and product promotions were $2,200,761 and $1,492,824 for the nine month period ended September&#13;30, 2014 and 2013, respectively.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In addition, the Company provides&#13;allowances for sales returns based upon estimated and known returns. Product returns are recorded as a reduction of net revenues&#13;and as a reduction of the accounts receivable balance.&lt;/font&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:CostOfSalesPolicyTextBlock contextRef="From2014-01-01to2014-09-30">&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Cost of Sales&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The Company purchases its products&#13;directly from third party manufacturers. The Company&amp;#146;s cost of sales include product costs, including any associated materials&#13;used in production, cost of warehousing and distribution. Included in the cost of sales are transit freight and shipping and handling&#13;costs that are incurred by the Company.&lt;/font&gt;&lt;/p&gt;</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2014-01-01to2014-09-30">&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Income Taxes&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The Company utilizes the asset&#13;and liability method of accounting for income taxes. Under this asset and liability method, deferred tax assets and liabilities&#13;are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying&#13;amounts of existing assets and liabilities, and their respective tax bases. Deferred tax assets and liabilities are measured using&#13;enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. &lt;/font&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:AdvertisingCostsPolicyTextBlock contextRef="From2014-01-01to2014-09-30">&lt;p style="margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Marketing&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The Company expenses all production&#13;costs related to advertising costs as they are incurred, including print, digital, and television when the advertisement has been&#13;broadcast or otherwise finished and or distributed. The Company records website costs related to its direct-to-consumer advertisements&#13;in accordance with FASB ASC 340-20 &amp;#147;Capitalized Advertising Costs&amp;#148;. In accordance with FASB ASC 340-20, direct response&#13;advertising costs incurred should be reported as assets and should be amortized over the estimated period of the benefits, based&#13;on the proportion of current period revenue from the advertisements to probable future revenue.&lt;/font&gt;&lt;/p&gt;</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2014-01-01to2014-09-30">&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Research and Development Costs&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Research and development costs,&#13;which includes the funding of clinical research studies, as well as creation and development of new products, are expensed when&#13;incurred.&lt;/font&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShippingAndHandlingCostPolicyTextBlock contextRef="From2014-01-01to2014-09-30">&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Distribution, Shipping and&#13;Handling Costs&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Shipping costs on purchases and&#13;shipping and handling fees related to sales charged to customers are both included in cost of sales. As mentioned in Revenue Recognition,&#13;shipping and handling revenue billed customers are reflected in other revenues.&lt;/font&gt;&lt;/p&gt;</us-gaap:ShippingAndHandlingCostPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2014-01-01to2014-09-30">&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Concentration of Credit Risk&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Financial instruments that potentially&#13;subject the Company to concentration of credit risk consist principally of trade accounts receivables. Concentrations of credit&#13;with respect to trade receivables are limited due to the large number of customers comprising the Company&amp;#146;s customer bases&#13;and their dispersion across different geographic locations.&lt;/font&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:UseOfEstimates contextRef="From2014-01-01to2014-09-30">&lt;p style="margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Use of Estimates&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The preparation of the financial&#13;statements in conformity with accounting principles generally accepted in the United States of America requires management to&#13;make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements&#13;and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&#13;Significant estimates include but are not limited to the fair value determination of derivative instruments, the valuation allowance&#13;with respect to estimated utilization of net operating losses, estimated allowances for sales returns and collectability of trade&#13;receivables.&lt;/font&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2014-01-01to2014-09-30">&lt;p style="margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Earnings (Loss) Per Share&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="text-align: justify; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Net earnings (loss) per share&#13;is computed by dividing net income (loss) less preferred dividends for the period by the weighted average number of shares of&#13;common stock outstanding during each period. Diluted earnings (loss) per share is computed by dividing net income (loss) less&#13;preferred dividends for the period by the weighted average number of shares of common stock, common stock equivalents and potentially&#13;dilutive securities outstanding during each period.&lt;/font&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:FairValueByBalanceSheetGroupingTextBlock contextRef="From2014-01-01to2014-09-30">&lt;table cellspacing="0" cellpadding="0" style="margin-top: 0px; font-size: 9pt; width: 100%"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="5" style="border-bottom: #000000 1px solid; vertical-align: bottom; font-size: 8.5pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;September&#13;    30, 2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; font-size: 8.5pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="5" style="border-bottom: #000000 1px solid; vertical-align: bottom; font-size: 8.5pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;December&#13;    31, 2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: #000000 1px solid"&gt;&lt;p style="font-size: 8.5pt; text-align: center; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Carrying&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;        &lt;p style="font-size: 8.5pt; text-align: center; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: #000000 1px solid; font-size: 8.5pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Fair&#13;    Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: #000000 1px solid"&gt;&lt;p style="font-size: 8.5pt; text-align: center; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Carrying&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;        &lt;p style="font-size: 8.5pt; text-align: center; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: #000000 1px solid; font-size: 8.5pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Fair&#13;    Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: #ebebff"&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Cash and cash equivalents&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 10px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right; width: 65px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,153,865&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 10px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 10px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right; width: 66px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,153,865&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 10px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 10px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right; width: 65px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;822,876&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 10px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 10px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right; width: 65px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;822,876&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Receivables&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,893,580&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,893,580&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,398,178&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,398,178&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: #ebebff"&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Accounts Payable&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,276,642&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,276,642&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,248,490&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,248,490&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Derivative Liability&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;226,445&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;226,445&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;471,015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;471,015&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:FairValueByBalanceSheetGroupingTextBlock>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock contextRef="From2014-01-01to2014-09-30">&lt;table cellspacing="0" cellpadding="0" style="width: 100%; margin-top: 0px; font-size: 9pt"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: #000000 1px solid; vertical-align: bottom"&gt;&lt;p style="font-size: 8.5pt; text-align: center; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;September&#13;                                         30,&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;        &lt;p style="font-size: 8.5pt; text-align: center; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; font-size: 8.5pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: #000000 1px solid; vertical-align: bottom"&gt;&lt;p style="font-size: 8.5pt; text-align: center; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;December&#13;                                         31,&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;        &lt;p style="font-size: 8.5pt; text-align: center; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: #ebebff"&gt;&#13;    &lt;td style="vertical-align: bottom; width: 71%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Trade Receivables&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right; width: 13%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,834,174&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right; width: 13%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,323,522&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Other&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;59,406&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;74,656&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: #ebebff"&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Allowance for doubtful accounts&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 1px solid; vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 1px solid; vertical-align: top; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(0)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 1px solid; vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 1px solid; vertical-align: top; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(0)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Totals&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 3px double; vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 3px double; vertical-align: top; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,893,580&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 3px double; vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 3px double; vertical-align: top; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,398,178&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="From2014-01-01to2014-09-30">&lt;table cellspacing="0" cellpadding="0" style="width: 100%; margin-top: 0px; font-size: 9pt"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: #000000 1px solid; vertical-align: bottom"&gt;&lt;p style="font-size: 8.5pt; text-align: center; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;September&#13;                                         30,&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;        &lt;p style="font-size: 8.5pt; text-align: center; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; font-size: 8.5pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: #000000 1px solid; vertical-align: bottom"&gt;&lt;p style="font-size: 8.5pt; text-align: center; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;December&#13;                                         31,&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;        &lt;p style="font-size: 8.5pt; text-align: center; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: #ebebff"&gt;&#13;    &lt;td style="vertical-align: bottom; width: 70%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Labels and packaging&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 2%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right; width: 13%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;170,189&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right; width: 13%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;120,057&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Raw materials&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;284,560&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;207,320&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: #ebebff"&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Finished goods&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 1px solid; vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 1px solid; vertical-align: top; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,191,558&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 1px solid; vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 1px solid; vertical-align: top; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,658,387&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Totals&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 3px double; vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 3px double; vertical-align: top; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,646,307&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 3px double; vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 3px double; vertical-align: top; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,985,764&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2014-01-01to2014-09-30">&lt;table cellspacing="0" cellpadding="0" style="margin-top: 0px; font-size: 9pt; width: 100%"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="vertical-align: bottom"&gt;&lt;p style="font-size: 8.5pt; text-align: center; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Three&#13;                                         Months Ended&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;        &lt;p style="font-size: 8.5pt; text-align: center; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;September&#13;        30,&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; font-size: 8.5pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="vertical-align: bottom"&gt;&lt;p style="font-size: 8.5pt; text-align: center; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Nine&#13;                                         Months Ended&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;        &lt;p style="font-size: 8.5pt; text-align: center; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;September&#13;        30,&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font-size: 8.5pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-size: 8.5pt; width: 18px"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 1px solid; font-size: 8.5pt; text-align: center; width: 73px"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-size: 8.5pt; width: 7px"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 1px solid; font-size: 8.5pt; text-align: center; width: 73px"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-size: 8.5pt; width: 5px"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 1px solid; font-size: 8.5pt; text-align: center; width: 73px"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-size: 8.5pt; width: 7px"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 1px solid; font-size: 8.5pt; text-align: center; width: 73px"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #ebebff"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Basic weighted average common shares outstanding&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-size: 8.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;12,892,515&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;12,878,216&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;12,886,216&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;12,730,371&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Stock options (exercise price &amp;#150; $0.573-$2.50/share)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;334,647&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;430,132&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;398,922&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;460,587&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #ebebff"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Warrants (exercise price &amp;#150; $0.001-$2.25/share)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;417,418&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;426,744&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;418,226&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;432,280&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total common stock equivalents&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;13,644,580&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;13,735,092&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;13,703,364&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;13,623,238&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock contextRef="From2014-01-01to2014-09-30">&lt;table cellspacing="0" cellpadding="0" style="margin-top: 0px; font-size: 9pt; width: 100%"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="8" style="border-bottom: #000000 1px solid; vertical-align: bottom; font-size: 8.5pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;September&#13;    30, 2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; font-size: 8.5pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="8" style="border-bottom: #000000 1px solid; vertical-align: bottom; font-size: 8.5pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;December&#13;    31, 2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font-size: 8.5pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font-size: 8.5pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Level&#13;    1&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-size: 8.5pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font-size: 8.5pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Level&#13;    2&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-size: 8.5pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font-size: 8.5pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Level&#13;    3&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-size: 8.5pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font-size: 8.5pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Level&#13;    1&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-size: 8.5pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font-size: 8.5pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Level&#13;    2&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-size: 8.5pt"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font-size: 8.5pt; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Level&#13;    3&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font-size: 8.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-top: #000000 1px solid; font-size: 8.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-size: 8.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-top: #000000 1px solid; font-size: 8.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-size: 8.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-top: #000000 1px solid; font-size: 8.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-size: 8.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-top: #000000 1px solid; font-size: 8.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-size: 8.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-top: #000000 1px solid; font-size: 8.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-size: 8.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-top: #000000 1px solid; font-size: 8.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #ebebff"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Balance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 3px double; width: 6px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 3px double; text-align: right; width: 56px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;42,311&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 6px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 3px double; width: 6px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 3px double; text-align: right; width: 55px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 7px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 3px double; width: 6px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 3px double; text-align: right; width: 59px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;226,445&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 6px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 3px double; width: 6px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 3px double; text-align: right; width: 56px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;108,228&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 6px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 3px double; width: 6px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 3px double; text-align: right; width: 58px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 6px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 3px double; width: 6px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 3px double; text-align: right; width: 61px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;471,015&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Beginning of Period&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;108,228&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;471,015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;29,338&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;701,852&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #ebebff"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Deletions&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(115,881)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(36,103)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(87,755)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Revisions&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 1px solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 1px solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;49,964&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 1px solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 1px solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 1px solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 1px solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(244,570)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 1px solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 1px solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;114,993&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 1px solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 1px solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 1px solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 1px solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(143,082)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #ebebff"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;End of Period&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 3px double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 3px double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;42,311&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 3px double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 3px double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 3px double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 3px double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;226,445&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 3px double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 3px double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;108,228&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 3px double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 3px double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 3px double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: #000000 3px double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;471,015&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
    <ifit:TotalCommonStockEquivalents contextRef="From2014-01-01to2014-09-30" unitRef="Shares" decimals="INF">13703364</ifit:TotalCommonStockEquivalents>
    <ifit:TotalCommonStockEquivalents contextRef="From2014-07-01to2014-09-30" unitRef="Shares" decimals="INF">13644580</ifit:TotalCommonStockEquivalents>
    <ifit:TotalCommonStockEquivalents contextRef="From2013-07-01to2013-09-30" unitRef="Shares" decimals="INF">13735092</ifit:TotalCommonStockEquivalents>
    <ifit:TotalCommonStockEquivalents contextRef="From2013-01-01to2013-09-30" unitRef="Shares" decimals="INF">13623238</ifit:TotalCommonStockEquivalents>
    <us-gaap:LineOfCreditFacilityExpirationDate1 contextRef="From2014-01-01to2014-09-30">2015-11-16</us-gaap:LineOfCreditFacilityExpirationDate1>
    <us-gaap:LineOfCreditFacilityCovenantTerms contextRef="From2014-01-01to2014-09-30">The agreement requires the Company to comply with certain affirmative covenants, including a minimum current ratio of 1.5 to 1, a maximum leverage ratio of 2 to 1, and minimum tangible equity capital of $2,750,000 through November 30, 2014, and $3,000,000 thereafter, as well as providing limitations on dividends, additional indebtedness, and certain other changes.</us-gaap:LineOfCreditFacilityCovenantTerms>
    <us-gaap:LineOfCreditFacilityCovenantCompliance contextRef="From2014-01-01to2014-09-30">As of September 30, 2014, the Company was in compliance with the credit facility covenants.</us-gaap:LineOfCreditFacilityCovenantCompliance>
    <us-gaap:LesseeLeasingArrangementsOperatingLeasesTermOfContract contextRef="From2014-10-01to2014-10-30_us-gaap_SubsequentEventMember_custom_LeaseArrangementTypeMember">P50M</us-gaap:LesseeLeasingArrangementsOperatingLeasesTermOfContract>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="From2014-01-01to2014-09-30" unitRef="Shares" decimals="INF">9701</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:AmortizationOfFinancingCosts contextRef="From2014-01-01to2014-09-30" unitRef="USD" decimals="0">0</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="From2013-01-01to2013-09-30" unitRef="USD" decimals="0">4375</us-gaap:AmortizationOfFinancingCosts>
</xbrli:xbrl>